What Valencia Technologies does

Valencia Technologies is a neuromodulation medical device company that developed and commercialized the eCoin System, the first and only FDA PMA-approved fully integrated, subcutaneously implantable tibial nerve stimulator for the treatment of urgency urinary incontinence (UUI), the most bothersome symptom of overactive bladder (OAB). Founded in 2011 and headquartered in Valencia, California, the company addresses a large underserved patient population—over 40 million women in the US suffer from UUI. The eCoin device is a coin-sized, leadless neurostimulator containing a primary-cell battery (1–8 year service life depending on amplitude) that is implanted subcutaneously near the ankle during a minimally invasive outpatient procedure of approximately 20 minutes under local anesthetic; it automatically delivers intermittent stimulation to the tibial nerve twice weekly via a forgiving dome-shaped stimulation field, with no lead wires, external remotes, recharging, or patient device management required. In the pivotal trial, 75% of patients (per protocol) achieved at least a 50% reduction in UUI episodes at one year, with an 89% recommendation rate and a 2.3% infection rate.

The company generates revenue through unit hardware sales of the eCoin device to hospitals, ambulatory surgery centers, and physician practices, reimbursed under Category III CPT code 0816T (APC 5464) at approximately $21,063 in the Medicare Hospital Outpatient setting and $19,464 in the ASC setting for CY2025. Distribution is via a direct enterprise sales force targeting urologists, urogynecologists, and female pelvic medicine specialists who must complete the eCoin Physician Qualification training program before implantation; patient access is supported by a partnership with PRIA Healthcare for prior-authorization and payer education. By May 2024, more than 1,100 patients in the US had been treated with eCoin. In February 2025, Valencia received up to $35 million in strategic investment from Brooks Advisory Group and appointed Jim Surek as CEO; in January 2026, Boston Scientific announced an agreement to acquire the company, completing the acquisition in April 2026 and integrating eCoin into its urology and pelvic health portfolio.

Name

Valencia Technologies

Legal name

Valencia Technologies Corporation

Website

https://valenciatechnologies.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

101–250 employees

Short description

Valencia Technologies is a neuromodulation medical device company that developed the eCoin System, the first FDA PMA-approved leadless implantable tibial nerve stimulator for urgency urinary incontinence. The company was acquired by Boston Scientific in April 2026.

Ownership category

akta.pro rank

Product category

Implantable Neuromodulation Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Continence Care Products (Adult Incontinence Pads/Briefs, Underpads, External Collectors) (HLAHALAH)

Keywords

• Implantable neurostimulators
• Tibial nerve stimulation
• Urinary incontinence treatment
• Neuromodulation medical devices
• Bladder dysfunction therapy

Headquarters

HQ city

Valencia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. eCoin Device Sales: Valencia Technologies generates revenue from the sale of its eCoin implantable tibial nerve stimulation device to hospitals, ambulatory surgery centers, and physician practices for the treatment of urgency urinary incontinence.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels10 records

Core offering

Valencia Technologies designs, manufactures, and sells the eCoin System, a coin-sized, leadless, FDA PMA-approved implantable tibial neurostimulator that automatically delivers intermittent stimulation to the tibial nerve for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. The device is implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic and is sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the United States.

Product overview

Valencia Technologies is a neuromodulation company with a single core product offering: the eCoin System. The eCoin System is a pioneering, leadless implantable tibial nerve stimulator (ITNS) for treating urgency urinary incontinence (UUI), the primary symptom of overactive bladder. The company operates as a medical device manufacturer and has been acquired by Boston Scientific (April 2026). The eCoin device is the first and only FDA PMA-approved fully integrated, subcutaneously implantable medical device designed to automatically stimulate the tibial nerve.

Differentiator

Problem solved

Functional benefit

Brands

• eCoin: The eCoin system is a coin-sized implantable tibial nerve stimulator for treating urge urinary incontinence (UUI). It is the first and only FDA-approved fully implantable device for this indication.

Products and services

• eCoin System Coin-sized, leadless implantable neurostimulator that automatically delivers intermittent stimulation to the tibial nerve twice weekly for the treatment of urgency urinary incontinence (UUI) secondary to overactive bladder. Implanted subcutaneously near the ankle during a ~20-minute outpatient procedure under local anesthetic. FDA PMA-approved and sold to urologists, urogynecologists, hospitals, and ambulatory surgery centers in the U.S.

Quantifiable outcome

• 75% responder rate (at least 50% reduction in UUI episodes at one year, per protocol population)
• +6 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• PRIA HealthcarecoreImplementation/ SI/ Consulting Partner · 10 May 2022Valencia retained PRIA Healthcare to assist in patient access for the FDA-approved eCoin device. PRIA develops patient-centric prior authorization and appeals programs, leverages clinical evidence to inform payors, and educates insurance companies on the clinically supported benefits of eCoin. PRIA has 10 years of experience assisting MedTech companies with patient access to new medical devices.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Medtronic plc: Medtronic's InterStim sacral neuromodulation system is the dominant FDA-approved implantable therapy for refractory urge urinary incontinence, making it the closest direct competitor to Valencia's eCoin ITNS in target indication, customer (urologists), and treatment modality (implantable neurostimulation).
• Axonics, Inc. Axonics offers the r-SNM sacral neuromodulation system for OAB and urge incontinence, directly competing with eCoin for the same urology/urogynecology channel and FDA-approved implantable neurostimulation category.

Broad incumbents

• Abbott Laboratories: Abbott's neuromodulation division (inherited from St. Jude Medical) sells Proclaim DRG and Proclaim Elite neurostimulators and is a broad incumbent in implantable neurostimulation across multiple indications, providing competitive overlap in physician mindshare and hospital contracting.
• Boston Scientific Corporation: Boston Scientific is Valencia's acquirer (April 2026) and operates a broader neuromodulation and pelvic-health portfolio including spinal cord stimulators, urogynecology slings, and the Greenlight laser system, into which eCoin is now integrated.
• Laborie Medical Technologies (Cogentix): Laborie, which acquired Cogentix/Endo International's urology business, is a broader urology device incumbent offering diagnostic and therapeutic OAB products, providing a comparable specialty channel and customer base for incontinence therapies.

Emerging players

• Inspire Medical Systems: Inspire's hypoglossal nerve stimulation implant for obstructive sleep apnea shares the same business model as Valencia: a single FDA-approved implantable neurostimulator targeting a specific specialty indication, with analogous reimbursement, sales-force build-out, and adoption curve.
• Nuvectra Corporation: Nuvectra developed Algovita and other implantable neurostimulators for pain and urology indications, providing a peer in the specialty implantable neuromodulation category with similar stage and commercialization challenges.
• Cala Health: Cala Health develops wearable transcutaneous neurostimulation devices for chronic conditions (essential tremor, etc.), offering a comparable neuromodulation platform targeting a defined specialty channel but with a non-invasive delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/valenciaecoin
• Facebookfacebook.com/valenciatechnologies
• LinkedInlinkedin.com/company/valencia-technologies-corporations

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valencia Technologies